Biotech Values

[DrBengtP]

Thanks for your answer and for directing me to Dr. Petrylak's presentation - I hadn't seen it before.

It really looks like there is synergy between docetaxel and Provenge, but I'm not quite sure what to read from the KM graph showing the survival of the 51+31=82 patients in D9901+D9902A who received docetaxel. Thus, considering the timing of the Provenge studies and the timing of the docetaxel approval, it seems impossible that anyone could have received docetaxel (and died after being on a Provenge study for only 6-9 months (the approximate time for the first death on the KM curve). So what is it actually that is shown on the graph? Is there an obvious answer that I missed?

Basically, I try to piece together a coherrent picture of what the data are, and such a discrepancy-look-alike like the one I mentioned above - while perhaps not obviously crucial - may still be interesting.

Thanks!
B.